Physical, but not laboratory, treatment-related adverse events are associated with favorable outcomes of enfortumab vedotin for advanced urothelial carcinoma: A landmark analysisSatoru Taguchi, Haruki Kume, Michio Noda et al.|Research Square|2024Cited by 2
Efficacy of Early Switching From Docetaxel to Cabazitaxel in Castration‐Resistant Prostate CancerTaketo Kawai, Haruki Kume, Kazuki Maki et al.|The Prostate|2025Cited by 1